Trial Profile
Bioequivalence Study of Mesylate Imatinib Capsule in Chronic Myeloid Leukemia Body
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 Jan 2019
Price :
$35
*
At a glance
- Drugs Imatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Pharmacokinetics
- Sponsors Chia Tai Tianqing Pharmaceutical Group
- 18 May 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 26 Feb 2013 New trial record